McMillan Office’s Merck MRK Stock Holding History

McMillan Office’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.1M	Sell	31,930 -40	-0.1%	-$4.68K	0.47%	34
2026 Q1	$3.85M	Sell	31,970 -3,299	-9%	-$381K	0.49%	34
2025 Q4	$3.71M	Buy	+35,269	New	+$3.31M	0.45%	37

Other funds holding MRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

McMillan Office's MRK Position: Q2 2026 in Review

McMillan Office reduced its Merck (MRK) stake by 0.13% in Q2 2026, selling an estimated $4.68K and leaving 31,930 shares worth $4.1M. The position accounts for 0.47% of the portfolio, ranked #34.

McMillan Office first reported a position in MRK in Q4 2025 and has held it in 3 quarters since. 3,824 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

McMillan Office held 31,930 shares of Merck worth $4.1M as of Q2 2026.
McMillan Office sold 40 Merck shares in Q2 2026, an estimated $4.68K.
Merck made up 0.47% of McMillan Office's portfolio in Q2 2026, its #34 holding.
McMillan Office first reported a position in Merck in Q4 2025 and has held it in 3 quarters since.
3,824 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on McMillan Office's 13F filing for Q2 2026, filed 13 Aug 2026.